Lipid and thyroid hormone levels in children with epilepsy treated with levetiracetam or carbamazepine: A prospective observational study
| Autor: | Hiroshi Yamaguchi, Noriyuki Nishimura, Kazumi Tomioka, Masahiro Nishiyama, Daisaku Toyoshima, Azusa Maruyama, Yusuke Ishida, Kandai Nozu, Tsukasa Tanaka, Taku Nakagawa, Kazumoto Iijima, Yuichi Takami, Shoichi Tokumoto, Hiroaki Nagase |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Levetiracetam Adolescent Antiepileptic drugs Thyrotropin 03 medical and health sciences Behavioral Neuroscience chemistry.chemical_compound Epilepsy 0302 clinical medicine Internal medicine medicine Humans Prospective Studies 030212 general & internal medicine Child Children Triglycerides medicine.diagnostic_test Triglyceride business.industry Cholesterol HDL Thyroid Cholesterol LDL Carbamazepine Lipid medicine.disease Thyroid Diseases Thyroid hormone Thyroxine medicine.anatomical_structure Endocrinology Neurology chemistry Child Preschool Anticonvulsants Female Neurology (clinical) Thyroid function Lipid profile business 030217 neurology & neurosurgery medicine.drug Hormone |
| Zdroj: | Epilepsy & Behavior. 90:15-19 |
| ISSN: | 1525-5050 |
| Popis: | Although previous studies have investigated the influence of antiepileptic drugs (AEDs) on lipid profiles and thyroid hormone levels, there is little evidence regarding the effects of levetiracetam (LEV). Therefore, we conducted a prospective longitudinal study to evaluate the effects of LEV and carbamazepine (CBZ) treatment on lipid profile and thyroid hormone levels in patients newly diagnosed with epilepsy. Inclusion criteria were as follows: (a) age between 4 and 15 years, (b) diagnosis of epilepsy with at least two focal seizures within a year, and (c) newly treated with LEV or CBZ monotherapy. Serum lipid profile and thyroid hormone levels were measured before and after 1 and 6 months of AED initiation. Among the 21 included patients (LEV: 13 patients, CBZ: 8 patients), all but one patient in the LEV group continued AED monotherapy during the study period. Although triglyceride (TG) levels tended to be increased in the CBZ group (baseline: 58.3 ± 22.0 mg/dl, 1 month: 63.8 ± 21.6 mg/dl, 6 months: 92.3 ± 63.6 mg/dl, p = 0.22, analyses of variance (ANOVA)), there were no significant changes in total cholesterol (TC), TG levels, high-density lipoprotein cholesterol (HDL-C), or low-density lipoprotein cholesterol (LDL-C) in either group. Serum free thyroxine (fT4) levels were significantly decreased in the CBZ group (baseline: 1.15 ± 0.06 ng/dl, 1 month: 1.00 ± 0.16 ng/dl, 6 months: 0.98 ± 0.14 ng/dl, p = 0.03, ANOVA). In contrast, there were no significant changes in fT4 or thyroid-stimulating hormone (TSH) levels in the LEV group. The results of the present study suggest that LEV monotherapy does not affect lipid profile or thyroid function while CBZ monotherapy may cause thyroid dysfunction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect